



---

## ASX Announcement/Media Release

### **iSonea receives Subscriptions under Rights Issue and further Commitments to \$4.6m exceeding expectations**

- **Renounceable Rights Issue receives subscriptions and commitments at 107% of the shares offered in the Renounceable Rights Issue.**
- **\$600K of Rights Issue shares that were not underwritten successfully placed through Patersons Securities Limited.**
- **Firm commitments for a further \$300K of shares to be placed directly by the Company.**

**Sydney, Australia:** Medical technology company iSonea Ltd (ASX:ISN, OTC:ISOAY) has raised \$4.6 million by way of subscription under the renounceable rights issue that closed on 15 December 2011 and further commitments to subscribe.

Further to the announcement on 19 December 2011 and pursuant to the Company's Prospectus in respect of the renounceable rights issue dated 18 November 2011, the Company has allotted and issued 860,253,232 shares and 215,063,309 free-attaching options and will place a further 59,999,966 shares and 14,999,992 free-attaching options.

The issued shares and commitments in total represent 107% of the 860,253,232 shares offered to qualifying shareholders in the Renounceable Rights Issue that closed on 15 December 2011. The total amount raised before broker fees was \$4,611,266.

The ISN shares offered under the Rights Issue that were not underwritten, were successfully placed through leading Australian stockbroker, Patersons Securities Limited, whom was the lead underwriter to the Rights Issue, raising \$4,301,266. The Company has received firm commitments for the placement of a further 59,999,966 shares, which will raise \$300,000. This further placement will be made directly by the Company to overseas investors who were unable to participate in the Rights Issue, ahead of the US listing in early January 2012.

Chief Executive Officer, Mr. Michael Thomas, said interest in the Rights Issue demonstrated strong shareholder support for the Company's new management team and recognised the commercial potential of the Company's proprietary Acoustic Respiratory Monitoring™ technologies.

"This level of support affirms the strategic direction of our company into 2012," he said.



Mr. Thomas continued by saying, "Asthma and related pulmonary disorders are growing concerns in our communities and we have non-invasive technologies that help patients manage these conditions more efficiently.

"We thank shareholders for their vigorous support of the Company. This has provided the opportunity to facilitate our commercial development plan for these innovations."

Holding statements were dispatched to shareholders on Thursday 22 December 2011 in respect of the shares and options issued to them in accordance with the Rights Issue Timetable.

**For further information please contact:**

Mr. Michael Thomas  
Chief Executive Officer  
iSonea Limited  
+1 410-777-5251  
mthomas@iSoneaMed.com

Emma Power  
Media and Investor Relations  
Monsoon Communications  
(03) 9620 3333  
Emmap@monsoon.com.au

Thursday 29 December 2011

**website: [www.iSoneaMed.com](http://www.iSoneaMed.com)**

**About iSonea Limited**

iSonea Limited (formerly KarmelSonix) is an emerging medical technology company developing innovative, non-invasive Acoustic Respiratory Monitoring™ (ARM) devices and software for the management of asthma and related pulmonary disorders. ARM is a breakthrough in asthma management. ARM devices are more patient-friendly than traditional tests, addressing a huge unmet medical need for frequent asthma monitoring, which is routinely recommended to improve asthma control. iSonea's ARM technology makes accurate, consistent, frequent monitoring possible for any patient, anywhere, at anytime. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA, and the European Union CE. Specific Acoustic Respiratory Monitoring devices have been designed for intermittent or continuous monitoring applications in clinical settings and for consumer use in life's settings.